Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor cell membrane antigens recognized by natural killer (NK) cells are a diverse set of stress-induced or altered self-molecules expressed on the surface of transformed cells. These antigens serve as ligands for activating and inhibitory receptors on NK cells, dictating the balance between NK cell activation and tolerance towards tumor cells. Key examples include NKG2D ligands (MICA/B, ULBPs), NCR ligands (NKp30, NKp44, NKp46 ligands), and downregulation/loss of HLA class I molecules. Therapeutic strategies aim to enhance ligand expression for activating receptors or block inhibitory pathways, boosting anti-tumor NK cell activity.
Enhance ligand expression for activating receptors or block inhibitory pathways to boost anti-tumor activity mediated through the NK cell axis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor Cell Membrane Antigen (via Natural Killer Cell Recognition).